

Over 15 years of clinical experience combined across all indications in:†

Rheumatoid arthritis (RA) – 2009; Psoriatic arthritis (PsA) – 2014; Ankylosing spondylitis (AS) – 2014; Plaque psoriasis (PsO) – 2018; and Non-radiographic axial spondyloarthritis (nr-axSpA) - 2019[1,2]

CIMZIA (certolizumab pegol) in combination with MTX is indicated for:

- reducing signs and symptoms, including major clinical response, and reducing the progression of joint damage as assessed by X-ray, in adult patients with moderately to severely active RA.

CIMZIA alone or in combination with MTX is indicated for:

- reducing signs and symptoms and inhibiting the progression of structural damage as assessed by X-ray, in adult patients with moderately to severely active PsA who have failed one or more DMARDs.

CIMZIA is indicated for:

- reducing signs and symptoms in adult patients with moderately to severely active RA who do not tolerate MTX.
- reducing signs and symptoms in adult patients with active AS who have had an inadequate response to conventional therapy.
- the treatment of adults with severe active nr-axSpA with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence who have had an inadequate response to, or are intolerant to NSAIDs.
- the treatment of adult patients with moderate to severe PsO who are candidates for systemic therapy.

* Comparative clinical significance unknown. † Clinical significance unknown.
CRP: C-reactive protein; DMARDs: disease-modifying anti-rheumatic drugs; MRI: magnetic resonance imaging; MTX: methotrexate; NSAIDs: nonsteroidal anti-inflammatory drugs; TNF: tumor necrosis factor alpha.

Consult the product monograph at https://www.ucbcanada.com/en/cimzia for important information about:

- Contraindications in active tuberculosis or other severe infections such as sepsis, abscesses and opportunistic infections; and moderate to severe heart failure (NYHA Class III/IV)
- The most serious warnings and precautions regarding serious infections and malignancy
- Other relevant warnings and precautions regarding worsening congestive heart failure and new onset CHF; hepatitis B virus reactivation; hematological reactions; neurologic reactions; use in combination with other biologic medicines; monitoring for patients in surgery and those being switched to another biologic DMARD; hypersensitivity symptoms; latex sensitivity; formation of autoantibodies; administration of live or live-attenuated vaccines; use in patients with severe immunosuppression; possible erroneously elevated activated partial thromboplastin time (aPTT) assay results in patients without coagulation abnormalities; women of childbearing potential; pregnancy and breastfeeding; caution in infants exposed in utero; caution in geriatric patients
- Conditions of clinical use, adverse reactions, drug interactions and dosing instructions

The product monograph is also available through Medical Information Services at 1-866-709-8444.

1. CIMZIA® Product Monograph. UCB Canada Inc. November 13, 2019.
2. Health Canada Notice of Compliance Database. Available at https://health-products.canada.ca/noc-ac/?lang=eng. Accessed January 9, 2025.

CRA-25-TBDE

REVIEWED BY PAAB

cimzia® (certolizumab pegol)